Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. (Q34539324)

2 August 2017

0 references

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. (English)

1 reference

2 August 2017

0 references

0 references

0 references

Salvador Resino

5

0 references

author name string

María A Jiménez-Sousa

1

1 reference

2 August 2017

Amanda Fernández-Rodríguez

2

1 reference

2 August 2017

María Guzmán-Fulgencio

3

1 reference

2 August 2017

Mónica García-Álvarez

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

8 January 2013

1 reference

2 August 2017

1 reference

2 August 2017

volume

11

1 reference

2 August 2017

page(s)

6

1 reference

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Frequency of IL28B rs12979860 Single-Nucleotide Polymorphism Alleles in Newborn Infants and in Patients with Chronic Hepatitis C in Morocco

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Lymphotropic hepatitis C virus has an interferon‐resistant phenotype

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Response-guided telaprevir combination treatment for hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Hepatitis C pharmacogenetics: state of the art in 2010.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Diagnosis, management, and treatment of hepatitis C: an update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Distributions of Hardy-Weinberg equilibrium test statistics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Genetic variation, classification and 'race'

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Statistical aspects of the analysis of data from retrospective studies of disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Meta-analysis, funnel plots and sensitivity analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

An illustrated guide to the methods of meta-analysis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

A note on graphical presentation of estimated odds ratios from several clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

A consumer's guide to subgroup analyses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Pharmacogenetics of hepatitis C.

7 July 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Random-effects model for meta-analysis of clinical trials: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Association of IL28B variants with response to pegylated‐interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Association of Genetic Variation in Il28B with Hepatitis C Treatment-Induced Viral Clearance in the Chinese Han Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B and interferon‐gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV‐HCV‐coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Early anemia and rapid virological response improve the predictive efficiency of IL28B‐genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Meta‐analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon‐α and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Boceprevir for Chronic HCV Genotype 1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3570369

The GATE frame: critical appraisal with pictures

27 October 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186/1741-7015-11-6

High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23298311

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1741-7015-11-6

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference